The Meso Foundation announced today that at the end of this month, Dr. Lee Krug’s term on the Board of Directors (BOD) of the Mesothelioma Applied Research Foundation will end. Dr. Krug joined the Foundation’s board in 2011, after several years serving on the organization’s Science Advisory Board (SAB). Dr. Krug led the organization as […]
Melissa Culligan, a member of the Mesothelioma Applied Research Foundation’s Board of Directors started her work on Saturday, December 3 at the 17th World Conference on Lung Cancer (WCLC), held in Vienna, Austria by attending an all day working meeting focused on the development of an Immunotherapy Guideline for clinicians. This working meeting was held […]
Results from studies using PDL1 inhibitors
Today, at the World Conference on Lung Cancer 2016 (Mesothelioma Track), several investigators presented data for their immunotherapy studies. The first three presentations focused on PDL1 inhibitors.
Dr. Paul Baas began the session by presenting data from his Phase II study of nivolumab, an immunotherapy agent. Though his study showed no […]
“Mesothelioma is known as a traditionally under-funded and under-studied cancer.”
That’s the answer customarily given to patients, their families, and the public at large when they ask about the very slow advances that were so typical of mesothelioma. Until now.
And while technically that is still true, especially when compared to other cancers, some changes are […]
This week, representatives of the Mesothelioma Applied Research Foundation are attending one of the largest medical conferences in the world: the World Conference on Lung Cancer, organized by the International Association for the Study of Lung Cancer. The conference which this year has an attendance of over 6,000 delegates, includes a full track dedicated to […]